246 related articles for article (PubMed ID: 17699574)
1. Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines.
Gasteiger G; Kastenmuller W; Ljapoci R; Sutter G; Drexler I
J Virol; 2007 Nov; 81(21):11925-36. PubMed ID: 17699574
[TBL] [Abstract][Full Text] [Related]
2. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo.
Drexler I; Antunes E; Schmitz M; Wölfel T; Huber C; Erfle V; Rieber P; Theobald M; Sutter G
Cancer Res; 1999 Oct; 59(19):4955-63. PubMed ID: 10519409
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction.
Behboudi S; Moore A; Gilbert SC; Nicoll CL; Hill AV
Vaccine; 2004 Oct; 22(31-32):4326-31. PubMed ID: 15474725
[TBL] [Abstract][Full Text] [Related]
4. Modified Vaccinia Virus Ankara Can Induce Optimal CD8
Wong YC; Croft S; Smith SA; Lin LCW; Cukalac T; La Gruta NL; Drexler I; Tscharke DC
J Virol; 2019 Nov; 93(21):. PubMed ID: 31375596
[TBL] [Abstract][Full Text] [Related]
5. Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect.
Brandler S; Lepelley A; Desdouits M; Guivel-Benhassine F; Ceccaldi PE; Lévy Y; Schwartz O; Moris A
J Virol; 2010 May; 84(10):5314-28. PubMed ID: 20219934
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor 3 promotes cross-priming to virus-infected cells.
Schulz O; Diebold SS; Chen M; Näslund TI; Nolte MA; Alexopoulou L; Azuma YT; Flavell RA; Liljeström P; Reis e Sousa C
Nature; 2005 Feb; 433(7028):887-92. PubMed ID: 15711573
[TBL] [Abstract][Full Text] [Related]
7. Modified vaccinia virus Ankara-infected dendritic cells present CD4+ T-cell epitopes by endogenous major histocompatibility complex class II presentation pathways.
Thiele F; Tao S; Zhang Y; Muschaweckh A; Zollmann T; Protzer U; Abele R; Drexler I
J Virol; 2015 Mar; 89(5):2698-709. PubMed ID: 25520512
[TBL] [Abstract][Full Text] [Related]
8. CTL induction by cross-priming is restricted to immunodominant epitopes.
Pavelic V; Matter MS; Mumprecht S; Breyer I; Ochsenbein AF
Eur J Immunol; 2009 Mar; 39(3):704-16. PubMed ID: 19189311
[TBL] [Abstract][Full Text] [Related]
9. Antigen bias in T cell cross-priming.
Wolkers MC; Brouwenstijn N; Bakker AH; Toebes M; Schumacher TN
Science; 2004 May; 304(5675):1314-7. PubMed ID: 15166378
[TBL] [Abstract][Full Text] [Related]
10. The role of membrane fusion activity of a whole inactivated influenza virus vaccine in (re)activation of influenza-specific cytotoxic T lymphocytes.
Budimir N; Meijerhof T; Wilschut J; Huckriede A; de Haan A
Vaccine; 2010 Dec; 28(52):8280-7. PubMed ID: 20965298
[TBL] [Abstract][Full Text] [Related]
11. Visualizing priming of virus-specific CD8+ T cells by infected dendritic cells in vivo.
Norbury CC; Malide D; Gibbs JS; Bennink JR; Yewdell JW
Nat Immunol; 2002 Mar; 3(3):265-71. PubMed ID: 11828323
[TBL] [Abstract][Full Text] [Related]
12. Mini-review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming?
Melief CJ
Eur J Immunol; 2003 Oct; 33(10):2645-54. PubMed ID: 14515248
[TBL] [Abstract][Full Text] [Related]
13. The cross-priming pathway: a portrait of an intricate immune system.
Basta S; Alatery A
Scand J Immunol; 2007 Apr; 65(4):311-9. PubMed ID: 17386021
[TBL] [Abstract][Full Text] [Related]
14. Recombinant murine gammaherpesvirus 68 (MHV-68) as challenge virus to test efficacy of vaccination against chronic virus infections in the mouse model.
El-Gogo S; Staib C; Meyr M; Erfle V; Sutter G; Adler H
Vaccine; 2007 May; 25(20):3934-45. PubMed ID: 17433507
[TBL] [Abstract][Full Text] [Related]
15. Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: indications for cross-priming.
Huckriede A; Bungener L; Holtrop M; de Vries J; Waarts BL; Daemen T; Wilschut J
Vaccine; 2004 Mar; 22(9-10):1104-13. PubMed ID: 15003637
[TBL] [Abstract][Full Text] [Related]
16. CD8+ T cell cross-priming via transfer of proteasome substrates.
Norbury CC; Basta S; Donohue KB; Tscharke DC; Princiotta MF; Berglund P; Gibbs J; Bennink JR; Yewdell JW
Science; 2004 May; 304(5675):1318-21. PubMed ID: 15166379
[TBL] [Abstract][Full Text] [Related]
17. Cellular protein is the source of cross-priming antigen in vivo.
Shen L; Rock KL
Proc Natl Acad Sci U S A; 2004 Mar; 101(9):3035-40. PubMed ID: 14978273
[TBL] [Abstract][Full Text] [Related]
18. New tools for antigen delivery to the MHC class I pathway.
Morón G; Dadaglio G; Leclerc C
Trends Immunol; 2004 Feb; 25(2):92-7. PubMed ID: 15102368
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death.
Kim JH; Kang TH; Noh KH; Bae HC; Kim SH; Yoo YD; Seong SY; Kim TW
Immunol Lett; 2009 Jan; 122(1):58-67. PubMed ID: 19135479
[TBL] [Abstract][Full Text] [Related]
20. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
